NCT04018885 - A Study on Safety and Preliminary Efficacy of ALA in Acne Vulgaris | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 11, 2019

Primary Completion Date

January 20, 2020

Study Completion Date

January 20, 2020

Conditions

Acne Vulgaris

Interventions

DRUG

ALA 2.5%

Topical treatment for photodynamic therapy, after drug incubation subsequent illumination with red light (72 J/cm2). 4 treatments at an interval of 10 (± 4) days.

DRUG

ALA 5%

Topical treatment for photodynamic therapy, after drug incubation subsequent illumination with red light (72 J/cm2). 4 treatments at an interval of 10 (± 4) days.

DRUG

ALA 10%

Topical treatment for photodynamic therapy, after drug incubation subsequent illumination with red light (72 J/cm2). 4 treatments at an interval of 10 (± 4) days.

Trial Locations (4)

200040

Huashan Hospital, Shanghai

Unknown

Hospital for Skin Diseases, Chinese Academy of Medical Sciences, Nanjing

Shanghai Dermatology Hospital, Shanghai

The General Hospital of the People's Liberation Army, Beijing

All Listed Sponsors

lead

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

INDUSTRY